Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Lenvaxen 4 mg
Lenvatinib Mesylate 4mg capsules – Everest Pharmaceuticals Ltd.
Approved for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC); first-line unresectable hepatocellular carcinoma (HCC); advanced renal cell carcinoma (RCC) with everolimus or pembrolizumab; and advanced endometrial carcinoma (non-MSI-H/non-dMMR) with pembrolizumab after prior systemic therapy.
- Clinical outcomes at a glance
18.3 mo
Median PFS vs 3.6 months with placebo in radioactive iodine-refractory differentiated thyroid cancer (SELECT trial, HR 0.21)
REFLECT
Non-inferior OS vs sorafenib with superior PFS and ORR in first-line unresectable HCC — first positive Phase 3 vs active comparator in HCC
Dissolvable
Capsules may be dissolved in water or apple juice — a clinically useful administration option for patients who cannot swallow capsules whole
FGFR1-4
Simultaneous VEGFR + FGFR inhibition — closes off both primary and backup angiogenic pathways that pure anti-VEGFR therapy leaves open
- Am I a candidate? — Take Decesion
1
Confirm which indication applies and the correct dose
Dosing differs by indication and — for HCC — by body weight. For endometrial carcinoma, confirm the tumor is non-MSI-H and non-dMMR (mismatch repair proficient), as the pembrolizumab combination is specifically approved for this subtype, not MSI-H tumors.
2
Blood pressure must be controlled before starting
Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, then at least monthly. Withhold for uncontrolled grade 3 hypertension; discontinue for life-threatening hypertension. This structured monitoring schedule is more specific than most drugs in this series.
3
Baseline liver, kidney, cardiac, and thyroid function assessment
Hepatotoxicity, renal failure, cardiac failure, and hypothyroidism have all been reported. Baseline testing and a monitoring plan for each are part of standard pre-treatment evaluation — with dose adjustments specified for severe hepatic or renal impairment.
4
QT interval — review medications that may prolong QT
Lenvatinib has been reported to prolong the QT/QTc interval. Coadministration with other QT-prolonging medications should be avoided. A baseline ECG and electrolyte assessment are appropriate, particularly in patients on medications with QT-prolonging potential.
Important safety information: Hypertension — control before starting; structured BP monitoring schedule required (after 1 week, then every 2 weeks for 2 months, then monthly). Cardiac failure, arterial thromboembolic events, hepatotoxicity, renal failure/impairment, proteinuria, QT prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome (RPLS), hemorrhagic events, GI perforation/fistula, hypothyroidism, and wound healing complications have all been reported. Embryo-fetal toxicity — effective contraception required during treatment and for at least 30 days after the final dose.
- common side effects to know
- Hypertension (most common grade 3/4 AE)
- Fatigue / diarrhea / decreased appetite
- Weight loss / arthralgia / nausea
- Dysphonia / hypothyroidism / proteinuria
- Cardiac failure / arterial thromboembolism
- Hepatic failure / renal failure / RPLS
- Trust & expertise
- FDA Approved 2015, Expanded 2016–2021
- EMA Approved 2015
- NCCN Thyroid / HCC / RCC / Endometrial Guidelines
- SELECT / REFLECT / CLEAR / KEYNOTE-775 Trials
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“The structured blood pressure monitoring schedule — after 1 week, every 2 weeks for 2 months, then monthly — is unusually specific compared to most oncology drugs and reflects how consistently and early hypertension develops in clinical practice. I also make sure patients know the capsule dissolution option: leaving capsules in water or apple juice for 10 minutes before drinking is a genuinely useful alternative for patients who struggle to swallow capsules whole, and this flexibility is confirmed in the prescribing information.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
We covered this in full detail just a few pages back for the Lenvanix page — here’s the complete set pulled forward rather than repeating the research.
Before confirming lenvatinib as your treatment
- Which specific indication applies to me — differentiated thyroid cancer, HCC, RCC, or endometrial carcinoma?
- Is this monotherapy, with everolimus, or with pembrolizumab?
- For endometrial carcinoma: has my tumor been confirmed as non-MSI-H and non-dMMR?
- What is my correct starting dose — and for HCC, has my body weight confirmed whether I’m on 12mg or 8mg?
- Are there clinical trials I should know about?
About hypertension — the most important pre-treatment and ongoing conversation
- Is my blood pressure currently controlled before starting?
- What is the specific monitoring schedule — after 1 week, every 2 weeks for 2 months, then monthly?
- What readings would trigger a dose interruption or reduction?
- What symptoms of severely elevated blood pressure should prompt same-day contact versus emergency care?
About QT prolongation
- Am I on any medications with known QT-prolonging potential that should be avoided or reviewed?
- Will I have a baseline ECG and electrolyte assessment?
About cardiac, liver, kidney, and thyroid monitoring
- Will baseline assessments be done for all four before starting?
- For HCC: how will treatment-related hepatotoxicity be distinguished from my underlying liver disease?
- What symptoms — yellowing, dark urine, shortness of breath, swollen legs, reduced urination — prompt urgent calls?
- Will thyroid function be monitored throughout treatment?
About RPLS — reversible posterior leukoencephalopathy syndrome
- What symptoms — severe headache, confusion, visual disturbances, seizures — should prompt immediate emergency evaluation?
About GI risk, wound healing, and surgical planning
- Do I have any GI history increasing perforation or fistula risk?
- If I have any surgery planned, how long before and after should lenvatinib be stopped?
About the capsule dissolution option
- Can I dissolve the capsules in water or apple juice if I have difficulty swallowing them whole?
- The protocol is: capsules in 1 tablespoon of liquid for 10 minutes, stir 3 minutes, drink, then add another tablespoon to rinse the glass — can you confirm this is appropriate for my situation?
About dosing and administration
- Should all doses be taken at the same time each day, and does food matter?
- What should I do if I miss a dose — I understand it should not be taken within 12 hours of the next scheduled dose?
About drug interactions
- Are there strong CYP3A4 inhibitors, inducers, or QT-prolonging medications I should avoid?
- If I’m prescribed something new by another doctor, what should they know?
About contraception
- What contraception is required during treatment and for at least 30 days after the final dose?
About monitoring response and the longer road
- What imaging schedule will track whether this is working?
- How long am I expected to stay on this medication?
- If lenvatinib stops working, what would be considered next?
- Are there patient assistance programs through Eisai if cost is a concern?
A practical tip: The structured blood pressure monitoring schedule — after 1 week, every 2 weeks for the first 2 months, then monthly — is unusually specific for an oncology medication and exists because hypertension develops early, consistently, and sometimes severely. Ask your oncologist to schedule these BP checks proactively before you start rather than leaving them to be arranged reactively, and confirm you have a clear phone number to call same-day if your home blood pressure readings exceed a threshold you should agree on in advance.
compare with other therapies
We covered this comparison in full detail just a few pages back for the Lenvanix page — here are the key findings pulled forward concisely.
The REFLECT trial — the defining head-to-head comparison
Unlike most comparisons in this series that rely on cross-trial indirect comparisons, lenvatinib versus sorafenib in first-line HCC has a dedicated, large Phase 3 head-to-head trial. REFLECT enrolled 954 patients and directly compared the two drugs as first-line therapy for unresectable HCC.
Result: Lenvatinib demonstrated non-inferior overall survival to sorafenib, while showing statistically significant superiority on both progression-free survival and objective response rate — matching sorafenib on the hardest endpoint (survival) while clearly outperforming it on tumor control measures.
This was historically significant as the first positive Phase 3 trial against an active comparator in unresectable HCC, ending sorafenib’s eleven-year monopoly as the only validated first-line option.
Side effects — different profiles, not simply better or worse
Lenvatinib: more hypertension (45% vs 31%) and proteinuria (6% vs 2% at grade 3/4)
Sorafenib: more diarrhea (46% vs 39%) and hand-foot skin reaction
Neither drug is simply better tolerated — the practical choice can reasonably reflect which specific toxicity pattern is more manageable for an individual patient.
Dosing convenience — lenvatinib is meaningfully simpler
Lenvatinib: once daily, with or without food, weight-based for HCC
Sorafenib: twice daily, strict empty stomach requirement
Important HCC-specific caveats for lenvatinib
REFLECT excluded patients with ≥50% liver involvement, portal vein invasion of the main portal vein, and bile duct invasion — making the lenvatinib trial population somewhat more selected than SHARP’s sorafenib population.
Where both drugs sit in current first-line HCC practice
Both are now largely second-tier behind immunotherapy-based combinations (atezolizumab plus bevacizumab, durvalumab plus tremelimumab) at most major centers. Both remain guideline-supported first-line options when immunotherapy is unsuitable.
Bottom line
Lenvatinib is at least equivalent and in some measures superior to sorafenib for first-line HCC in eligible patients. The practical choice between them depends on the hypertension and proteinuria burden of lenvatinib versus sorafenib’s diarrhea and hand-foot skin reaction, plus lenvatinib’s more convenient once-daily dosing. Both sit behind immunotherapy-based combinations in most contemporary guidelines when those options are available and appropriate.
How does testing work
We covered this mechanism in full detail just a few pages back for the Lenvanix page — here are the key points pulled forward concisely.
The shared anti-angiogenic foundation — VEGFR blockade
Like sorafenib and cabozantinib, lenvatinib’s core mechanism begins with blocking VEGFR1, 2, and 3 on tumor blood vessel cells — cutting off the new blood supply cancers need to grow. This anti-angiogenic approach is shared across the entire class of multikinase TKIs in this conversation.
What makes lenvatinib structurally distinct — FGFR1 through FGFR4
Lenvatinib simultaneously inhibits the entire fibroblast growth factor receptor family (FGFR1, 2, 3, and 4), alongside VEGFR, PDGFRα, KIT, and RET. Sorafenib doesn’t meaningfully inhibit FGFR. Cabozantinib targets MET and AXL (different resistance pathways) but also lacks significant FGFR coverage. Lenvatinib is the only drug in this series that closes off both VEGFR and the entire FGFR pathway simultaneously.
Why FGFR matters — blocking the backup angiogenic escape route
When tumors are treated with anti-VEGFR drugs, they frequently upregulate FGF/FGFR signaling as a parallel escape route to sustain new blood vessel formation — routing around the VEGFR blockade through a separate but functionally equivalent angiogenic pathway. By blocking both VEGFR and FGFR simultaneously, lenvatinib cuts off both pathways at once, making it considerably harder for tumor vasculature to find an alternative blood supply compared to pure VEGFR-blocking drugs.
Why FGFR inhibition is specifically relevant in HCC
Some HCC tumors have particularly active FGFR signaling as a direct driver of proliferation, not just as a resistance escape route. Lenvatinib’s FGFR inhibition directly attacks this active growth signal — and its antiproliferative activity in HCC cell lines dependent on activated FGFR signaling, with concurrent inhibition of FRS2α phosphorylation, contributes to its higher objective response rates compared to sorafenib in REFLECT.
Why this explains the REFLECT efficacy pattern
Lenvatinib matched sorafenib on overall survival while outperforming it on PFS and ORR — the endpoints most directly reflecting immediate tumor control and shrinkage. A drug that simultaneously blocks VEGFR-driven and FGFR-driven angiogenesis, plus direct FGFR-driven tumor proliferation, mechanistically produces more complete and more rapid tumor responses than one blocking only VEGFR and RAF — exactly what the trial data showed.
Why hypertension is directly mechanism-linked
VEGFR2 inhibition reduces nitric oxide production in blood vessel walls, causing vasoconstriction and blood pressure elevation. Lenvatinib’s particularly potent VEGFR inhibition combined with FGFR-driven vascular effects produces a more pronounced hypertension signal than sorafenib — mechanistically explaining the 45% vs 31% hypertension difference in REFLECT and why blood pressure control is foundational before starting.
The bigger picture
Lenvatinib’s dual VEGFR/FGFR blockade — closing off both the primary and most common backup angiogenic pathway — is the most likely explanation for its superior PFS and ORR versus sorafenib. Not simply a more potent VEGFR blocker, but one that simultaneously prevents the FGFR-mediated escape that limits durability of pure VEGFR-blocking approaches.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
